Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Senti Biosciences announced its fourth quarter and full year 2025 financial results, marking significant progress in its clinical pipeline, particularly with SENTI-202 for relapsed/refractory acute myeloid leukemia (AML). The company reported positive preliminary Phase 1 clinical data, received FDA Regenerative Medicine Advanced Therapy designation…